Evidence map›Paper›PMID 34246041›Full record

Observational studyInternational immunopharmacology2021

Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.

Yurie Kobashi, Yoshitaka Nishikawa, Takeshi Kawamura, Tatsuhiko Kodama, Yuzo Shimazu, Daiji Obara, Tianchen Zhao, Masaharu Tsubokura

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yurie KobashiDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan. Electronic address: yurie-s@umin.ac.jp.
Yoshitaka NishikawaDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan.
Takeshi KawamuraLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan.
Tatsuhiko KodamaLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
Yuzo ShimazuSouthern Tohoku Research Institute for Neuroscience, 7-115, Yatsuyamada, Koriyama, Fukushima 963-8563, Japan.
Daiji ObaraDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan.
Tianchen ZhaoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Masaharu TsubokuraDepartment of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Fukushima Medical University · JPMurata (Japan) · JPSouthern Tohoku General Hospital · JPThe University of Tokyo · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Performing a cohort-based SARS-CoV-2 antibody assay is crucial for understanding infection status and future decision-making. The objective of this study was to examine consecutive antibody seroprevalence changes among hospital staff, a high-risk population. A two-time survey was performed in May and October 2020 for 545 hospital staff to investigate the changes in the results of the rapid kit test and chemiluminescence immunoassay (CLIA). The seroprevalence of each assay was summarized at both the survey periods. The proportion of seropositive individuals in the CLIA for each survey period and the number of confirmed COVID-19 cases in Central Fukushima were then compared. We chose 515 participants for the analysis. The proportion of IgM seroprevalence in CLIA increased from 0.19% in May to 0.39% in October, and IgG seroprevalence decreased from 0.97% in May to 0.39% in October. The proportion of IgM seroprevalence in the rapid kit test decreased from 7.96% in May to 3.50% in October, and IgG seroprevalence decreased from 7.77% in May to 2.14% in October. The IgG and IgM antibody seroprevalence among hospital staff in rural Central Fukushima decreased; the seroprevalence among hospital staff was consistent with the number of confirmed COVID-19 cases in the Central Fukushima area. Although it is difficult to interpret the results of the antibody assay in a population with a low prior probability, constant follow-up surveys of antibody titers among hospital staff had several merits in obtaining a set of criteria regarding the accuracy of measures against COVID-19 and estimating the COVID-19 infection status among hospital staff.

Indexed as

Personnel, HospitalRural HealthAdultAntibodies, ViralAntigens, ViralBiomarkersCase-Control StudiesCOVID-19FemaleHumansImmunoglobulin GImmunoglobulin MJapanMaleMiddle AgedPopulation SurveillanceAntibodies, ViralAntigens, ViralBiomarkersImmunoglobulin GImmunoglobulin MAntibody prevalenceCohort studyCOVID-19Serological assay

Identifiers

PMID34246041
PMCPMC8200307
OpenAlexW3170493478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.